Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large distant deletion disrupts CDKN2A enhancer and predisposes to melanoma.

medRxiv : the preprint server for health sciences·2026
Same author

Whole genome sequencing in oesophageal adenocarcinoma unmasks potential precision therapies.

BMC cancer·2026
Same author

SUMOylation of EphB4 enhances its stability in prostate cancer.

British journal of cancer·2026
Same author

Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature.

Cell reports. Medicine·2026
Same author

Agent-MIRA: AI-orchestrated medical imaging agent for PET image retrieval and assistance.

Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society·2026
Same author

Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Related Experiment Video

Updated: May 24, 2026

DNA-barcode-based Multiplex Immunofluorescence Imaging to Analyze FFPE Specimens from Genetically Reprogrammed Murine Melanoma
09:58

DNA-barcode-based Multiplex Immunofluorescence Imaging to Analyze FFPE Specimens from Genetically Reprogrammed Murine Melanoma

Published on: June 6, 2025

A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.

Ken Dutton-Regester1, Darryl Irwin, Priscilla Hunt

  • 1Queensland Institute of Medical Research, Oncogenomics Laboratory, Queensland University of Technology, Brisbane, Queensland. ken.dutton-regester@qimr.edu.au

Molecular Cancer Therapeutics
|March 3, 2012
PubMed
Summary

This study developed a cost-effective, high-throughput mutation panel for melanoma, identifying key genetic mutations like BRAF and NRAS. This panel aids in selecting personalized, molecularly targeted therapies for melanoma patients.

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Experiment Videos

Last Updated: May 24, 2026

DNA-barcode-based Multiplex Immunofluorescence Imaging to Analyze FFPE Specimens from Genetically Reprogrammed Murine Melanoma
09:58

DNA-barcode-based Multiplex Immunofluorescence Imaging to Analyze FFPE Specimens from Genetically Reprogrammed Murine Melanoma

Published on: June 6, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Personalized therapeutics rely on identifying specific tumor mutations for targeted drug efficacy.
  • Melanoma treatment efficacy is linked to the presence or absence of actionable mutations.

Purpose of the Study:

  • To develop a high-throughput mutation panel for identifying clinically relevant mutations in melanoma.
  • To facilitate the selection of molecularly targeted drugs for melanoma treatment.

Main Methods:

  • Literature review and database interrogation (Catalogue of Somatic Mutations in Cancer) identified over 1,000 melanoma mutations.
  • Initial screening of 120 mutations in 271 samples using Sequenom MassARRAY.
  • Design of 46 assays targeting 39 mutations in 20 genes for a melanoma-specific panel.

Main Results:

  • BRAF (57%), NRAS (20%), CDK4 (3%), PTK2B (2.5%), and ERBB4 (2%) were the most frequent mutations identified.
  • The final panel consists of 46 assays in 8 multiplexed wells, optimized for sensitive mutation detection.
  • The panel is cost-effective, sensitive, and high-throughput for identifying clinically relevant melanoma mutations.

Conclusions:

  • The developed melanoma-specific mutation panel enables rapid and accurate identification of mutations.
  • This panel supports the selection of effective molecularly targeted treatment strategies for melanoma.
  • It advances personalized therapeutic approaches in melanoma treatment.